Journal article

In vitro characterization of Pittsburgh compound-B binding to Lewy bodies

Michelle T Fodero-Tavoletti, David P Smith, Catriona A McLean, Paul A Adlard, Kevin J Barnham, Lisa E Foster, Laura Leone, Keyla Perez, Mikhalina Cortes, Janetta G Culvenor, Qiao-Xin Li, Katrina M Laughton, Christopher C Rowe, Colin L Masters, Roberto Cappai, Victor L Villemagne

JOURNAL OF NEUROSCIENCE | SOC NEUROSCIENCE | Published : 2007

Abstract

Dementia with Lewy bodies (DLB) is pathologically characterized by the presence of alpha-synuclein-containing Lewy bodies within the neocortical, limbic, and paralimbic regions. Like Alzheimer's disease (AD), Abeta plaques are also present in most DLB cases. The contribution of Abeta to the development of DLB is unclear. [11C]-Pittsburgh compound B ([11C]-PIB) is a thioflavin-T derivative that has allowed in vivo Abeta burden to be quantified using positron emission tomography (PET). [11C]-PIB PET studies have shown similar high cortical [11C]-PIB binding in AD and DLB subjects. To establish the potential binding of PIB to alpha-synuclein in DLB patients, we characterized the in vitro bindin..

View full abstract